Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended September 30, 2002
Industry: Medical Technology
Overview: BD manufactures and sells medical supplies, devices, laboratory equipment, and diagnostic products. Operations are organized into three segments: BD Medical Systems (injection systems, diabetes care, infusion therapy), BD Clinical Laboratory Solutions (microbiology, sample collection, hematology), and BD Biosciences (life sciences research tools). The company operates globally with significant manufacturing and sales outside the United States.
Key Financial Metrics
Note: Specific revenue, profit, cash flow, and debt figures for the fiscal year are incorporated by reference to the 2002 Annual Report (pages 22-37) and are not explicitly detailed in the provided text. The following metrics are available from the filing text:
- Research & Development (R&D) Spend: Approximately $220 million for fiscal 2002 (compared to $212 million in 2001 and $224 million in 2000).
- Employee Count: 25,249 employees as of September 30, 2002 (11,487 in the U.S.).
- Shareholder Base: Approximately 10,035 shareholders of record as of November 30, 2002.
- Equity Compensation: As of September 30, 2002, 30,608,303 securities were to be issued upon exercise of outstanding options, with a weighted-average exercise price of $26.02.
- Valuation Accounts: Total balance for doubtful accounts and cash discounts against trade receivables was $38,019,000 at period end.
Material Changes and Operational Highlights
- Leadership Transition: Edward J. Ludwig became Chairman, President, and Chief Executive Officer in February 2002. William A. Kozy was appointed President of BD Clinical Laboratory Solutions and Company Operations in May 2002.
- Strategic Divestiture: Negotiations for the sale of BD's critical care product line to AorTech International plc were terminated in August 2002.
- Revenue Recognition: Approximately 11% of total revenues in fiscal 2002 came from a single distributor supplying Medical Systems and Clinical Laboratory Solutions products.
- Property Utilization: BD owns and leases approximately 13.8 million square feet of facilities globally. The company reports facilities are fully utilized and operating at normal capacity.
Outlook, Risks, and Contingencies
Management Commentary and Guidance
Management revised previous earnings guidance in September 2002 following the termination of negotiations to sell the critical care product line. Forward-looking statements are subject to risks including foreign exchange fluctuations, competitive pricing pressures, and healthcare cost containment trends.
Legal Proceedings and Contingencies
- Latex Glove Litigation: BD is a defendant in approximately 520 product liability lawsuits regarding natural rubber latex allergies. While 227 cases have been closed with no liability and 14 settled for de minimis amounts, the company is vigorously defending the remainder. Reserves have been established for defense costs.
- Needlestick Litigation: BD faces six pending product liability lawsuits regarding accidental needlesticks. Class certification was denied in Illinois and Texas but certified in Ohio (currently under appeal). BD opposes class certification in other jurisdictions.
- Antitrust Litigation: Retractable Technologies, Inc. filed an antitrust lawsuit alleging BD conspired to exclude it from the market. A trial date is set for April 8, 2003. BD is vigorously defending the matter.
- Environmental Matters: BD is involved in Superfund proceedings. While management believes current reserves are adequate, future charges could materially affect results if liabilities exceed estimates.
Key Risk Factors
- Fluctuations in foreign currency exchange rates impacting profitability.
- Dependence on sole-source suppliers for certain raw materials.
- Regulatory changes and pricing pressures from healthcare consolidation and managed care.
- Potential product recalls or safety concerns.
Investor Verification Checklist
- Financial Statements: Verify specific revenue, net income, and cash flow figures in the "Ten-Year Summary" and "Financial Review" sections of the 2002 Annual Report (incorporated by reference).
- Legal Reserves: Assess the adequacy of reserves for the pending latex and needlestick litigation, particularly given the class certification ruling in Ohio.
- Antitrust Exposure: Monitor the progress of the Retractable Technologies antitrust trial scheduled for April 2003.
- Divestiture Impact: Evaluate the financial impact of the failed sale of the critical care product line on future earnings guidance.
- Supply Chain: Review the list of sole-source raw material suppliers to assess supply continuity risks.